Fig. 2. Female Sexual Function Index–desire domain (FSFI–D) (A) and Female Sexual Distress Scale–Desire/Arousal/Orgasm (FSDS-DAO) item 13 scores (B) throughout RECONNECT studies for the open-label extension population and General Assessment Questionnaire (GAQ) question 3 mean score by visit (C). A. FSFI-D scores range from 1.2 to 6.0, with higher scores indicating greater sexual desire. Reference 25 explains the scoring system for the FSFI-D (see Appendix B in that article). B. Item 13 asks, “How often do you feel bothered by low sexual desire?” Scores range from 0 to 4, where 0=never; 1=rarely; 2=occasionally; 3=frequently; 4=always. C. GAQ question 3 asks, “Compared with the start of the study [before taking the study drug], to what degree do you think you benefited from taking the study drug?” Scores range from 1 (very much worse) to 7 (very much better); a score of 5 or higher indicates benefit. BMT, bremelanotide; OLE, open-label extension.

Simon. Long-term Safety and Efficacy of Bremelanotide. Obstet Gynecol 2019.